414 related articles for article (PubMed ID: 32526061)
1. Targeting the NO-cGMP-PDE5 pathway in COVID-19 infection. The DEDALO project.
Isidori AM; Giannetta E; Pofi R; Venneri MA; Gianfrilli D; Campolo F; Mastroianni CM; Lenzi A; d'Ettorre G
Andrology; 2021 Jan; 9(1):33-38. PubMed ID: 32526061
[TBL] [Abstract][Full Text] [Related]
2. Targeting the SARS-CoV-2 3CL
Shirvaliloo M
Future Cardiol; 2021 Aug; 17(5):765-768. PubMed ID: 33576273
[No Abstract] [Full Text] [Related]
3. Phosphodiesterase 5 (PDE5) inhibition, ANP and NO rapidly reduce epididymal duct contractions, but long-term PDE5 inhibition in vivo does not.
Mietens A; Tasch S; Feuerstacke C; Eichner G; Volkmann J; Schermuly RT; Grimminger F; Müller D; Middendorff R
Mol Cell Endocrinol; 2012 Feb; 349(2):145-53. PubMed ID: 21996373
[TBL] [Abstract][Full Text] [Related]
4. Phosphodiesterase type 5 (PDE5) is co-localized with key proteins of the nitric oxide/cyclic GMP signaling in the human prostate.
Ückert S; Waldkirch ES; Merseburger AS; Kuczyk MA; Oelke M; Hedlund P
World J Urol; 2013 Jun; 31(3):609-14. PubMed ID: 23475211
[TBL] [Abstract][Full Text] [Related]
5. The NO/cGMP/PKG pathway in platelets: The therapeutic potential of PDE5 inhibitors in platelet disorders.
Degjoni A; Campolo F; Stefanini L; Venneri MA
J Thromb Haemost; 2022 Nov; 20(11):2465-2474. PubMed ID: 35950928
[TBL] [Abstract][Full Text] [Related]
6. Phosphodiesterase 5 (PDE5): Structure-function regulation and therapeutic applications of inhibitors.
Ahmed WS; Geethakumari AM; Biswas KH
Biomed Pharmacother; 2021 Feb; 134():111128. PubMed ID: 33348311
[TBL] [Abstract][Full Text] [Related]
7. Antenatal sildenafil treatment attenuates pulmonary hypertension in experimental congenital diaphragmatic hernia.
Luong C; Rey-Perra J; Vadivel A; Gilmour G; Sauve Y; Koonen D; Walker D; Todd KG; Gressens P; Kassiri Z; Nadeem K; Morgan B; Eaton F; Dyck JR; Archer SL; Thébaud B
Circulation; 2011 May; 123(19):2120-31. PubMed ID: 21537000
[TBL] [Abstract][Full Text] [Related]
8. Could Oral Phosphodiesterase 5 Inhibitors Have a Potential Adjuvant Role in Combating COVID-19 Infection?
Mostafa T
Sex Med Rev; 2021 Jan; 9(1):15-22. PubMed ID: 33077403
[TBL] [Abstract][Full Text] [Related]
9. Brief hyperoxia increases mitochondrial oxidation and increases phosphodiesterase 5 activity in fetal pulmonary artery smooth muscle cells.
Farrow KN; Lee KJ; Perez M; Schriewer JM; Wedgwood S; Lakshminrusimha S; Smith CL; Steinhorn RH; Schumacker PT
Antioxid Redox Signal; 2012 Aug; 17(3):460-70. PubMed ID: 22229392
[TBL] [Abstract][Full Text] [Related]
10. Phosphodiesterase 5 inhibition attenuates cerebral vasospasm and improves functional recovery after experimental subarachnoid hemorrhage.
Han BH; Vellimana AK; Zhou ML; Milner E; Zipfel GJ
Neurosurgery; 2012 Jan; 70(1):178-86; discussion 186-7. PubMed ID: 21796010
[TBL] [Abstract][Full Text] [Related]
11. Distinct allostery induced in the cyclic GMP-binding, cyclic GMP-specific phosphodiesterase (PDE5) by cyclic GMP, sildenafil, and metal ions.
Biswas KH; Visweswariah SS
J Biol Chem; 2011 Mar; 286(10):8545-8554. PubMed ID: 21193396
[TBL] [Abstract][Full Text] [Related]
12. The Role of PDE5 Inhibitors and the NO/cGMP Pathway in Cancer.
Peak TC; Richman A; Gur S; Yafi FA; Hellstrom WJ
Sex Med Rev; 2016 Jan; 4(1):74-84. PubMed ID: 27872007
[TBL] [Abstract][Full Text] [Related]
13. Development of novel phosphodiesterase 5 inhibitors for the therapy of Alzheimer's disease.
Zuccarello E; Acquarone E; Calcagno E; Argyrousi EK; Deng SX; Landry DW; Arancio O; Fiorito J
Biochem Pharmacol; 2020 Jun; 176():113818. PubMed ID: 31978378
[TBL] [Abstract][Full Text] [Related]
14. Cyclic-GMP-binding, cyclic-GMP-specific phosphodiesterase (PDE5) gene expression is regulated during rat pulmonary development.
Sanchez LS; de la Monte SM; Filippov G; Jones RC; Zapol WM; Bloch KD
Pediatr Res; 1998 Feb; 43(2):163-8. PubMed ID: 9475279
[TBL] [Abstract][Full Text] [Related]
15. Testosterone positively regulates functional responses and nitric oxide expression in the isolated human corpus cavernosum.
Gur S; Alzweri L; Yilmaz-Oral D; Kaya-Sezginer E; Abdel-Mageed AB; Dick B; Sikka SC; Volkan Oztekin C; Hellstrom WJG
Andrology; 2020 Nov; 8(6):1824-1833. PubMed ID: 32672414
[TBL] [Abstract][Full Text] [Related]
16. Cyclic GMP and cGMP-binding phosphodiesterase are required for interleukin-1-induced nitric oxide synthesis in human articular chondrocytes.
Geng Y; Zhou L; Thompson WJ; Lotz M
J Biol Chem; 1998 Oct; 273(42):27484-91. PubMed ID: 9765278
[TBL] [Abstract][Full Text] [Related]
17. Phosphodiesterase 5 inhibitors as novel agents for the treatment of Alzheimer's disease.
Liu L; Xu H; Ding S; Wang D; Song G; Huang X
Brain Res Bull; 2019 Nov; 153():223-231. PubMed ID: 31493542
[TBL] [Abstract][Full Text] [Related]
18. Roles of cGMP-dependent protein kinase I (cGKI) and PDE5 in the regulation of Ang II-induced cardiac hypertrophy and fibrosis.
Patrucco E; Domes K; Sbroggió M; Blaich A; Schlossmann J; Desch M; Rybalkin SD; Beavo JA; Lukowski R; Hofmann F
Proc Natl Acad Sci U S A; 2014 Sep; 111(35):12925-9. PubMed ID: 25139994
[TBL] [Abstract][Full Text] [Related]
19. Pulmonary vasodilation by phosphodiesterase 5 inhibition is enhanced and nitric oxide independent in early pulmonary hypertension after myocardial infarction.
van Duin RWB; Houweling B; Uitterdijk A; Duncker DJ; Merkus D
Am J Physiol Heart Circ Physiol; 2018 Feb; 314(2):H170-H179. PubMed ID: 28986358
[TBL] [Abstract][Full Text] [Related]
20. Compartmentation and compartment-specific regulation of PDE5 by protein kinase G allows selective cGMP-mediated regulation of platelet functions.
Wilson LS; Elbatarny HS; Crawley SW; Bennett BM; Maurice DH
Proc Natl Acad Sci U S A; 2008 Sep; 105(36):13650-5. PubMed ID: 18757735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
